Direkt zum Inhalt
Merck
Alle Fotos(1)

Wichtige Dokumente

Gesamtdokumentation anzeigen

N0850000

Nimodipin

European Pharmacopoeia (EP) Reference Standard

Synonym(e):

1,4-Dihydro-2,6-dimethyl-4-(3-nitrophenyl)-3,5-pyridindicarbonsäure-(2-methoxyethyl)-(1-methylethyl)-ester, Isopropyl-(2-methoxyethyl)-1,4-dihydro-2,6-dimethyl-4-(m-nitrophenyl)-3,5-pyridindicarboxylat

Anmeldenzur Ansicht organisationsspezifischer und vertraglich vereinbarter Preise
Alle Fotos(1)

About This Item

Empirische Formel (Hill-System):
C21H26N2O7
CAS-Nummer:
66085-59-4
Molekulargewicht:
418.44
MDL-Nummer:
MFCD00153848
UNSPSC-Code:
41116107
PubChem Substanz-ID:
329818466
NACRES:
NA.24

Qualität

pharmaceutical primary standard

API-Familie

nimodipine

Hersteller/Markenname

EDQM

Anwendung(en)

pharmaceutical (small molecule)

Format

neat

SMILES String

COCCOC(=O)C1=C(C)NC(C)=C(C1c2cccc(c2)[N+]([O-])=O)C(=O)OC(C)C

InChI

1S/C21H26N2O7/c1-12(2)30-21(25)18-14(4)22-13(3)17(20(24)29-10-9-28-5)19(18)15-7-6-8-16(11-15)23(26)27/h6-8,11-12,19,22H,9-10H2,1-5H3

InChIKey

UIAGMCDKSXEBJQ-UHFFFAOYSA-N

Angaben zum Gen

human ... CACNA1C(775) , CACNA1D(776) , CACNA1F(778) , CACNA1S(779) , NR3C2(4306)

Suchen Sie nach ähnlichen Produkten? Aufrufen Leitfaden zum Produktvergleich

Allgemeine Beschreibung

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.

Anwendung

Nimodipine EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.

Verpackung

The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.

Sonstige Hinweise

Sales restrictions may apply.

Ähnliches Produkt

Produkt-Nr.
Beschreibung
Preisangaben

N0850010

Nimodipin-Unreinheit A, European Pharmacopoeia (EP) Reference Standard

1463870

Nimodipin-verwandte Verbindung A, United States Pharmacopeia (USP) Reference Standard

1463858

Nimodipin, United States Pharmacopeia (USP) Reference Standard

1463869

Nimodipin-verwandte Verbindung B, United States Pharmacopeia (USP) Reference Standard

Y0001784

Nimodipin für die Peakidentifizierung, European Pharmacopoeia (EP) Reference Standard

BP651

Nimodipin, British Pharmacopoeia (BP) Reference Standard

75161

Bis(1-methylethyl)-2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridin-3,5-dicarboxylat, certified reference material, TraceCERT®, Manufactured by: Sigma-Aldrich Production GmbH, Switzerland

BP943

Nimodipin-Unreinheit A, British Pharmacopoeia (BP) Reference Standard

Piktogramme

Exclamation mark
GHS07

Signalwort

Warning

H-Sätze

H302

Gefahreneinstufungen

Acute Tox. 4 Oral

Lagerklassenschlüssel

11 - Combustible Solids

WGK

WGK 1

Flammpunkt (°F)

Not applicable

Flammpunkt (°C)

Not applicable

Hier finden Sie alle aktuellen Versionen:

Analysenzertifikate (COA)

Lot/Batch Number

Leider sind derzeit keine COAs für dieses Produkt online verfügbar.

Wenn Sie Hilfe benötigen, wenden Sie sich bitte an Kundensupport

Besitzen Sie dieses Produkt bereits?

In der Dokumentenbibliothek finden Sie die Dokumentation zu den Produkten, die Sie kürzlich erworben haben.

Die Dokumentenbibliothek aufrufen

W Mück et al.
Die Pharmazie, 49(2-3), 130-139 (1994-02-01)
The analytical test procedures currently established for the determination of the dihydropyridine calcium antagonist nimodipine in biological fluids are presented. Method of choice which has been dominantly used in pharmacokinetic investigations and drug interaction studies is gas chromatography with electron-capture
Potential interactions between nimodipine and adrenal hormones.
R L Isaacson et al.
Annals of the New York Academy of Sciences, 765, 134-142 (1995-09-15)
J Horn et al.
Stroke, 32(10), 2433-2438 (2001-10-06)
Based on the results of animal experiments, clinical trials were performed with nimodipine, which did not demonstrate a beneficial effect on outcome after stroke. The aim of this study was to determine whether the evidence from animal experiments with nimodipine
Daniele Tomassoni et al.
Clinical and experimental hypertension (New York, N.Y. : 1993), 30(8), 744-766 (2008-11-21)
Nimodipine is a 1,4-dihydropyridine-derivative Ca(2+)-channel blocker developed approximately 30 years ago. It is highly lipophilic, crosses the blood-brain barrier, and reaches brain and cerebrospinal fluid. Early treatment with nimodipine reduces the severity of neurological deficits resulting from vasospasm in subarachnoid
Clark A Rosen et al.
Muscle & nerve, 50(1), 114-118 (2014-03-19)
Nimodipine has been shown to be beneficial for recovery from acute vocal fold paralysis (AVFP) in an animal model. prospective, open-label trial of patients with AVFP was performed using nimodipine. Consecutive patients were evaluated and offered nimodipine therapy. Fifty-three patients
Alle zugehörigen Dokumente anzeigen

Unser Team von Wissenschaftlern verfügt über Erfahrung in allen Forschungsbereichen einschließlich Life Science, Materialwissenschaften, chemischer Synthese, Chromatographie, Analytik und vielen mehr..

Setzen Sie sich mit dem technischen Dienst in Verbindung.